{"entity":{"id":"clinical-breast-cancer","kind":"journal","name":"Clinical breast cancer","aka":["Clin Breast Cancer","Clinical Breast Cancer"],"tldr":"Clinical Breast Cancer is an Elsevier specialty journal for clinical and translational breast cancer research, from detection and prevention to treatment. Breast oncologists, surgeons and translational researchers read it.","summary":"Clinical Breast Cancer is a peer-reviewed journal that publishes original articles on clinical and translational research in breast cancer, with eight issues a year. Its aims and scope statement says it is devoted to detection, diagnosis, prevention and treatment of breast cancer, with emphasis on recent scientific developments, and lists clinical research reports across therapeutic modalities, cancer genetics, drug sensitivity and resistance, novel imaging, tumour genomics, biomarkers and chemoprevention strategies as areas of interest. The journal site includes an open access section for authors but does not state its overall access model in the text consulted, so no access model is recorded here. NLM records the title from 2000, first published in Dallas by the Cancer Information Group and since 2011 by Elsevier in New York, bimonthly from 2010 with supplements accompanying some volumes, and indexed in MEDLINE and PubMed.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.clinical-breast-cancer.com/"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/100898731"}],"tags":[],"related":["pubmed-europepmc"],"cancers":["breast-hr-positive","breast-her2-positive","tnbc","ductal-carcinoma-in-situ","male-breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Elsevier","url":"https://www.clinical-breast-cancer.com/","issn":"1526-8209","scope":"breast cancer","founded":2000,"matchNames":["Clin Breast Cancer","Clinical breast cancer","Clinical Breast Cancer"]},"route":"/journals/clinical-breast-cancer/","neighbours":{"collection":[{"id":"pubmed-europepmc","kind":"collection","name":"PubMed & Europe PMC","route":"/collections/pubmed-europepmc/"}],"cancer":[{"id":"ductal-carcinoma-in-situ","kind":"cancer","name":"Ductal carcinoma in situ (DCIS)","route":"/cancers/ductal-carcinoma-in-situ/"},{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"male-breast-cancer","kind":"cancer","name":"Male breast cancer","route":"/cancers/male-breast-cancer/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"paper":[{"id":"paper-hudson-phillips-expanded-germline-testing-clin-breast-cancer-2026","kind":"paper","name":"The impact of expanded access to germline high penetrance genetic testing for women with a new diagnosis of invasive breast cancer or high-grade DCIS","route":"/key-papers/paper-hudson-phillips-expanded-germline-testing-clin-breast-cancer-2026/"}],"person":[{"id":"emmanuel-barranger","kind":"person","name":"Emmanuel Barranger","route":"/people/emmanuel-barranger/"},{"id":"john-kennedy","kind":"person","name":"John Kennedy","route":"/people/john-kennedy/"}]}}